Seliciclib (roscovitine or CYC202) is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase or state within the cell cycle of treated cells. Seliciclib is being developed by Cyclacel.

CAS：186692-46-6
中文别名：细胞周期蛋白B激酶抑制剂;6-(苄基氨基)-2(R)-[[1-(羟甲基)丙基]氨基]-9-异丙基嘌呤;
英文别名：P34 CDC2;(R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol;Roscovitin;CYC202 Cyclacel;Seliciclib;CYC 202;R-roscovitine;Roscovitine;
分子式：C19H26N6O
分子量：354.449
精确质量：354.217
Psa：87.89
Logp：3.3481

MDL号：MFCD02266401

外观与性状：白色至灰白色固体
密度：1.25 g/cm C
沸点：577.5ºC at 760 mmHg
闪点：303.1ºC
折射率：1.643
储存条件：-20ºC
蒸汽压：3.52E-14mmHg at 25°C

安全说明：S22-S24/25
WGK Germany：3
海关编码：2933990090